Quantcast
Last updated on April 17, 2014 at 16:42 EDT

Ikaria® To Present At 2013 Bio Business Forum and International Convention

April 16, 2013

HAMPTON, N.J., April 16, 2013 /PRNewswire/ — Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2013 Biotechnology Industry Organization (BIO) Business Forum and International Convention taking place April 22-25, 2013 at McCormick Place in Chicago, IL. Mr. Tasse’s presentation will be given on Tuesday, April 23, 2013 at 2:00 p.m. CT in the Chicago Bulls Room.

About Ikaria, Inc.

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company’s lead product is INOMAX(®) (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse(®) DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria’s late-stage pipeline is also comprised of LUCASSIN(®) (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.

    Company Contact:       Media Contacts:

    Samina Bari            Claire Sojda

    Ikaria, Inc.           Tiberend Strategic Advisors, Inc.

    (908) 238-6372         (212) 375-2686

    samina.bari@ikaria.com csojda@tiberend.com

SOURCE Ikaria, Inc.


Source: PR Newswire